All In Biotech

Drug Trial Radar · NCT07295951

A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia

An Open-Label Study to Investigate the Absorption, Metabolism, And Excretion (AME) Of 14C-Bleximenib (JNJ-75276617) in Participants With Acute Leukemia

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

6

Actual

Start

Nov 18, 2025

Primary completion

Jul 21, 2026

Study completion Jul 21, 2026

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Dec 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess how the body absorbs, breaks down (metabolism), and removes (excretes) radiolabeled bleximenib (a drug molecule that has been chemically bonded with a radioactive isotope which emits radiation making it easier to track in the body) in participants with acute leukemia (highly aggressive blood cancer typically characterized by large numbers of immature white blood cells in the bone marrow).

Conditions

  • Acute Lymphoblastic Leukemia
  • Acute Leukemias
  • Acute Myeloid Leukemia

Interventions

  • 14C-bleximenibDrug

    14C-bleximenib will be administered orally.

  • bleximenibDrug

    Non-radiolabeled bleximenib will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Dose Excreted in Urine (feu)Time frame: Up to Day 28
  2. Percentage of Dose Excreted in Feces (fef)Time frame: Up to Day 28
  3. Amount Excreted in Urine (Aeu)Time frame: Up to Day 28
  4. Amount Excreted in Feces (Aef)Time frame: Up to Day 28
  5. Area Under the Concentration-Time Curve from Time 0 to the Last Measurable Concentration (AUC0-t)Time frame: Cycle 1 Day 1, and Cycle 1 Day 2 (Cycle duration=28 days)
  6. Maximum Observed Concentration (Cmax)Time frame: Cycle 1 Day 1, and Cycle 1 Day 2 (Cycle duration=28 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Christie NHS Foundation Trust Christie Hospital

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.